Cited by 15Advanced Glycation End Products researchGlycosylation and Glycoproteins ResearchProtein Interaction Studies and Fluorescence Analysis

Preferential recognition of advanced glycation end products by serum antibodies and low-grade systemic inflammation in diabetes mellitus and its complications

Raghav, Alok, Ahmad, Jamal, Alam, Khursheed·2018·International Journal of Biological Macromolecules

Abstract

Background Advanced glycation end products (AGEs) have shown to possess antigenicity. This study analyzes the detrimental effect of non-enzymatic glycation on human serum albumin (HSA) leading to the production of antibodies. Methods HSA (20 μM) incubated with d-glucose formed AGEs confirmed by scanning electron microscopy (SEM). DNA-damage was assessed with comet assay. Antibodies against in-vitro formed AGEs was evaluated in the sera of diabetic patients by enzyme-linked immunosorbent assay. Molecular docking was performed to demonstrate affinity of native and glycated-HSA with IgG. Low-grade systemic inflammation was quantified with IL-4, IL-6, TNF-α and NF-кβ in serum and mRNA expression. Results Scanning Electron Microscopy showed the formation of aggregates in glycated-HSA. Comet assay showed DNA damage T2DM with CKD. Serum auto-antibodies in diabetes patients with chronic kidney disease (CKD) showed appreciably high recognition with glycated-HSA compared to native HSA. Molecular docking showed less affinity of glycated-HSA with IgG. Serum IL-4, IL-6, and TNF-α were found significantly higher in T2DM with CKD compared to T2DM and healthy ones. mRNA expression of IL-4, IL-6 and NF-кβ are also found significantly higher in T2DM with CKD. Conclusion The non-enzymatic glycation-induced damage to the HSA generate neo-epitopes that possess immunogenic response and low-grade systemic inflammation.

Integrity signals

Registry

Crossref · 10.1016/j.ijbiomac.2018.07.033

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The AP-1 factors c-Jun and JunB are critical interacting partners with PU.1 that also regulate myeloid differentiation, including PU.1 expression.

    “Indeed, the AP-1 factors c-Jun and JunB are also critical interacting partners with PU.1 that also regulate myeloid differentiation (including PU.1 expression) (Steidl et al., 2006; Raghav et al., 2018; Zhao et al., 2022).”

    From PU.1 is required to restrain myelopoiesis during chronic inflammatory stress (2023) · cites this paper as Raghav et al., 2018

Cites

Flagged first, then by citations

1 of the 27 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Raghav, A., Ahmad, J., & Alam, K.
Affiliations
Aligarh Muslim University (IN)
Corresponding author
Ahmad, Jamal
Venue
International Journal of Biological Macromolecules
Publisher
Elsevier BV
Published
2018-10
Volume
118
Issue
Pt B
Pages
1884-1891
ISSN
0141-8130 (ISSN-L)
OpenAlex
W2883840479
Cited by
15
References
27
Citations by year
2026: 2 · 2024: 2 · 2023: 4 · 2021: 4 · 2019: 3
FWCI
1.36
Type
journal article
Language
en
Open access
closed
Locations
  • International Journal of Biological Macromolecules (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
Keywords
advanced glycation end products, glycation, human serum albumin, autoantibodies, type 2 diabetes, chronic kidney disease, low-grade inflammation, DNA damage, neoantigens, interleukin-6, IL-4, TNF-α, NF-κB, diabetes complications
MeSH terms
Diabetes Mellitus, Type 2, Female, Humans, Immunoglobulin G, Male, Middle Aged, Protein Binding, Protein Conformation, Serum Albumin, Substrate Specificity, Glycation End Products, Advanced, Molecular Docking Simulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review